Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 7, 2014, Pages 951-959

  Wirk, Baldeep ^a   Fenske, Timothy S ^b   Hamadani, Mehdi ^c   Zhang, Mei Jie ^d   Hu, Zhen Huan ^d   Akpek, Görgün ^e   Aljurf, Mahmoud D ^f   Armand, Philippe ^g   Ayala, Ernesto ^h   Bachanova, Veronika ⁱ   Bolwell, Brian ^j   Cairo, Mitchell S ^k   Cashen, Amanda ^l   Chen, Yi Bin ^m   Costa, Luciano J ⁿ   Farhan, Shatha ^o   Freytes, César O ^p   Gajewski, James L ^q   Gibson, John ^r   Hale, Gregory A ^s   Holmberg, Leona A ^t   Hsu, Jack W ^u   Inwards, David J ^v   Kamble, Rummurti T ^w   Maharaj, Dipnarine ^x   Maziarz, Richard T ^q   Munker, Reinhold ^y   Nath, Rajneesh ^z   Reddy, Nishitha M ^aa   Reeder, Craig B ^ab   Rizzieri, David A ^ac   Sauter, Craig S ^ad   Savani, Bipin N ^aa   Schouten, Harry C ^ae   Sureda, Anna ^af   Vose, Julie M ^ag   Waller, Edmund K ^ah   Wiernik, Peter H ^ai   Gale, Robert Peter ^aj   Burns, Linda J ⁱ   Saber, Wael ^d   more..

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^c WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e Banner MD Anderson Cancer Center   (United States)

^f KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k NEW YORK MEDICAL COLLEGE   (United States)

^l BARNES JEWISH HOSPITAL   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^o HENRY FORD HOSPITAL   (United States)

^p SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^q OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^r ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^s JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^t Fred Hutchinson Cancer Research Center   (United States)

^u UNIVERSITY OF FLORIDA   (United States)

^v MAYO CLINIC ROCHESTER   (United States)

^w CENTER FOR CELL AND GENE THERAPY   (United States)

^x Bethesda Health City   (United States)

^y LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^z UMASS MEMORIAL MEDICAL CENTER   (United States)

^aa VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ab PHOENIX CHILDREN'S HOSPITAL   (United States)

^ac DUKE UNIVERSITY MEDICAL CENTER   (United States)

^ad MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ae MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^af UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^ag NEBRASKA MEDICAL CENTER   (United States)

^ah EMORY UNIVERSITY   (United States)

^ai OUR LADY OF MERCY MEDICAL CENTER   (United States)

^aj IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Transformed follicular lymphoma; Transplant

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB; TOSITUMOMAB I 131;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HLA TYPING; HUMAN; KARNOFSKY PERFORMANCE STATUS; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; TUMOR VOLUME; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SURVIVAL; YOUNG ADULT;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902084890     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.014     Document Type: Article

References (38)

1. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
2. Novelli S., Briones J., Sierra J. Epidemiology of lymphoid malignancies: last decade update. Springerplus 2013, 2:70.
3. Al-Tourah A.J., Gill K.K., Chhanabhai M., et al. Population based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:5165-5169.
4. Bastion Y., Sebban C., Berger F., et al. Incidence, predictive factors, and outcomes of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997, 15:1587-1594.
5. Gine E., Montoto S., Bosch F., et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histologic subtype are the most important factors to predict histologic transformation in follicular lymphoma. Ann Oncol 2006, 17:1539-1545.
6. Montoto S., Davies A.J., Matthews J., et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:2426-2433.
7. Conconi A., Ponzio C., Lobetti-Bodoni C., et al. Incidence, risk factors and outcome of histologic transformation in follicular lymphoma. Br J Haematol 2012, 157:188-196.
8. Garvin A.J., Simon R.M., Osborne C.K., et al. An autopsy study of histologic progression in non-Hodgkin's lymphoma: 192 cases from the National Cancer Institute. Cancer 1983, 52:393-398.
9. Cohen Y., Da'as N., Libster D., et al. Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history or therapy related complication. Eur J Haematol 2002, 68:80-83.
10. Solal-Celigny P., Bellei M., Marchesselli L., et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012, 30:3848-3853.
11. Czuczman M.S., Vose J.M., Witzig T.E., et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histologic origin. Br J Haematol 2011, 154:477-481.
12. Molica S. A systematic review on Richter syndrome: what is the published evidence?. Leuk Lymphoma 2010, 51:415-421.
13. McNamara C., Davis J., Dyer M., et al. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 2012, 156:446-467.
14. Schouten H.C., Bierman P.J., Vaughan W.P., et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989, 74:2579-2584.
15. Chen C., Crump M., Tsang R., et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001, 113:202-208.
16. Hamadani M., Benson D.M., Lin T.S., et al. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 2008, 81:425-431.
17. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001, 19:727-735.
18. Friedberg J.W., Neuberg D., Gribben J.G., et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999, 5:262-268.
19. Ramadan K.M., Connors J.M., Al-Tourah A.J., et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008, 42:601-608.
20. Rezvani A., Storer B., Marris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:211-217.
21. Horowitz M. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant 2008, 42(Suppl 1):S1-S2.
22. World Health Organization classification of tumors: Pathology and genetics of tumors of hematopoietic and lymphoid tissues 2001, IARC Press, Lyon, France. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
23. Cheson B., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:1244-1253.
24. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
25. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
26. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
27. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
28. Cantor A.B. Projecting the standard error of the Kaplan-Meier estimator. Stat Med 2001, 20:2091-2097.
29. Clark T.G., Altman D.G., De Stavola B.L. Quantification of the completeness of follow-up. Lancet 2002, 359:1309-1310.
30. Ban-Hoefen M., Kelly J.L., Bernstein S.H., et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma 2012, 53:827-832.
31. Eide M.B., Lauritzsen G.F., Kvalhelm G., et al. High-dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphoma: a Norwegian multicenter phase II study. Br J Haematol 2011, 152:600-610.
32. Villa D., Crump M., Panzarella T., et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian Blood and Marrow Transplant Group. J Clin Oncol 2013, 31:1164-1171.
33. Yuen A.R., Kamel O.W., Halpern J., Horning S.J. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 1995, 13:1726-1733.
34. Fisher R.I., Kaminski M.S., Wahl R.L., et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphoma. J Clin Oncol 2005, 25:7565-7573.
35. Hamadani M., Awan F.T., Elder P., et al. Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma 2008, 49:1893-1898.
36. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
37. Urbano-Ispizua A., Pavletic S.Z., Flowers M.E.D., et al. Association of graft-versus-host disease (GVHD) with a lower relapse/progression rate after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning in patients with follicular and mantle cell lymphoma: a CIBMTR analysis [abstract]. Blood 2013, 122:2093.
38. Lazarus H.M., Zhang M.J., Carreras J., et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010, 16:35-45.